FDA Approves Once-Daily Psoriasis Pill With 70% Clear Skin Rate

Imagine waking up one day and seeing your skin clear for the first time in years. That's now possible for millions of Americans thanks to a breakthrough psoriasis treatment that just earned FDA approval.

Johnson & Johnson announced on March 18, 2026, that the FDA approved ICOTYDE (icotrokinra), the first oral pill that targets a specific immune protein responsible for the red, scaly patches that define psoriasis. The once-daily medication is approved for adults and teens 12 and older who weigh at least 88 pounds.

The numbers tell an impressive story. In clinical trials involving 2,500 patients, roughly 70% achieved clear or almost clear skin after 16 weeks. More than half saw a 90% improvement in their symptoms during the same timeframe.

What makes this approval even more remarkable is the safety profile. Patients taking ICOTYDE experienced side effects at rates just 1.1% higher than those taking a placebo through the first 16 weeks. No new safety concerns emerged even after a full year of treatment.

For people living with psoriasis, the condition goes far beyond appearance. The chronic inflammatory disease causes painful, itchy patches that can crack and bleed. Many patients struggle with daily activities, sleep disruption, and the emotional toll of a visible condition that affects more than 8 million Americans.

Traditional treatments have included topical creams, light therapy, and injectable medications. ICOTYDE offers a new option: a pill that blocks interleukin-23, a protein that drives the immune system to attack healthy skin cells.

The Ripple Effect

This approval represents more than just another treatment option. It signals a shift toward targeted therapies that address the root cause of autoimmune conditions rather than just masking symptoms.

The medication's convenience matters too. A once-daily pill eliminates the need for injections or frequent doctor visits for light therapy. That accessibility could help more people stick with treatment long enough to see real results.

For the roughly 30% of psoriasis patients who develop psoriatic arthritis, better skin control might offer hope for managing the joint inflammation that often follows. Early treatment of the underlying immune dysfunction could potentially slow disease progression.

The approval also opens doors for younger patients. Adolescents starting at age 12 can now access this targeted therapy during crucial developmental years when skin conditions can deeply affect self-esteem and social connections.

As ICOTYDE becomes available to patients, it joins a growing toolkit of precision medicines that are transforming how we treat chronic inflammatory diseases. For millions of people who've spent years searching for relief, clear skin is no longer just a dream but a realistic goal within reach.